NASA outlines four health and biology studies set to fly on SpaceX CRS-35

NASA said on October 12 that four health and biology investigations are scheduled to travel to the International Space Station aboard SpaceX’s CRS-35 cargo mission from Cape Canaveral Space Force Station in Florida. The work will test brain tissue models, plant disease, onboard biomarker measurement and the persistence of drug-resistant organisms. Each is a planned experiment; NASA has not reported results from this flight.

SpaceX lists launch from Space Launch Complex 40 for October 13 at 10:33 UTC, with a backup opportunity on October 14 at 10:08 UTC. Its mission page says Dragon is expected to dock autonomously with the station about 52 hours after launch, at approximately 15:00 UTC on October 15. Those are targets, and the research depends on the flight and station work still to come.

What the four CRS-35 investigations will test

For the brain study, researchers plan to send small lab-grown models of human brain tissue to the station for five weeks and compare them with identical models kept on Earth. NASA says the comparison is intended to examine how a short period of spaceflight affects cells. It presents a better understanding of stress and possible future risks to astronauts’ brain health as reasons for doing the work, rather than conclusions already drawn from it.

A separate plant experiment will compare crops grown on Earth with crops grown on the station after infection with a disease-causing fungus. Researchers will examine molecular and structural changes to test whether disease develops faster or more severely in microgravity. NASA identifies disease-resistant crop breeding and reduced losses as possible applications. Its announcement does not say the comparison has shown either outcome.

Why researchers will sample station surfaces again

The fourth investigation returns to the station for what NASA calls its final planned stay. Astronauts will repeatedly sample surfaces for drug-resistant organisms, giving researchers material to study how antibiotic-resistant bacteria survive and evolve in microgravity. The announcement describes the sampling plan but gives no result from this final stay. Repeated sampling is central to the question: it lets the investigation examine organisms found in the station environment over its planned visits, subject to what the samples actually show.

There is already a relevant research record, although it is separate from CRS-35. In a 2024 paper in Nature Communications, Iris Irby and Jared T. Broddrick analyzed 245 genomes from bacterial strains isolated on the station. They identified 283 complete prophages, of which 21% were novel, and reported correlations between functions associated with those prophages and traits linked to persistence, including antimicrobial resistance. Prophages are viral genetic sequences carried in bacterial genomes. The paper’s genomic correlations do not establish what the new surface samples will contain or whether the planned experiment will produce a particular health finding.

That distinction matters for interpreting the mission. The earlier study gives researchers a reason to examine microbial adaptation in the station environment, while NASA’s latest announcement sets out a further investigation. It does not show that CRS-35 has found a new resistant organism or that any proposed intervention works. The question for the returning study is what repeated samples reveal after the final planned station stay.

What remains unknown before launch and analysis

The four investigations address different practical concerns: how brain cells respond to spaceflight, how crop disease behaves away from Earth, whether a small reader can measure useful biomarkers aboard the station, and how resistant microbes persist there. NASA frames benefits to astronaut health and crops as potential applications. For now, the firm development is the research scheduled to fly, with launch, docking, experimental work and results still pending.

NASA’s announcement does not name the principal investigators, give detailed protocols for every study or specify when findings will be published. Those gaps limit what can be said about how the studies will be evaluated and when readers may see evidence of an outcome. The upcoming flight is an opportunity to collect and analyze data, and the claims about benefits will depend on that work rather than the cargo manifest alone.